Scarica l'app Stockscreener
6.46
2.86%
-0.19
Dopo l'orario di chiusura:
6.56
0.10
+1.55%
Precedente Chiudi:
$6.65
Aprire:
$6.77
Volume 24 ore:
1.25M
Relative Volume:
0.76
Capitalizzazione di mercato:
$374.90M
Reddito:
$217.11M
Utile/perdita netta:
$-651.19M
Rapporto P/E:
-0.4973
EPS:
-12.99
Flusso di cassa netto:
$-387.26M
1 W Prestazione:
-17.29%
1M Prestazione:
-52.32%
6M Prestazione:
+2.22%
1 anno Prestazione:
-86.20%
Intervallo 1D:
$6.33
$6.90
Intervallo di 1 settimana:
$6.33
$7.78
Portata 52W:
$5.26
$48.00
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Confronta DNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
6.46 | 374.90M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
SBI Securities Co. Ltd. Acquires Shares of 2,905 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why - MSN
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consort - GuruFocus.com
Ginkgo Bioworks (DNA) Insider Trading Activity 2025 - MarketBeat
Ginkgo Bioworks CFO sells shares worth $6,102 - Investing.com India
Ginkgo Bioworks CFO sells shares worth $6,102 By Investing.com - Investing.com Australia
Ginkgo Bioworks executive sells shares for over $3k - Investing.com
Y Intercept Hong Kong Ltd Purchases New Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
(DNA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 18, 2022DNA - ACCESS Newswire
Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight - GlobeNewswire Inc.
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Simply Wall St
Ginkgo Bioworks (DNA) Expected to Announce Earnings on Thursday - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Gap DownHere's What Happened - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Posts Quarterly Earnings Results, Misses Expectations By $0.37 EPS - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Posts Earnings Results - MarketBeat
DNA; SRNG Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors of Class Action and Deadline: January 18, 2022 - ACCESS Newswire
Ginkgo Bioworks Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Ginkgo Bioworks Shrinks Office and Lab Footprint in Boston, Cambridge - Connect CRE
Ginkgo Bioworks: Revenue Struggles Continue - Seeking Alpha
2025 Is Make Or Break For Ginkgo Bioworks (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Holdings Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Ginkgo Bioworks: Key Takeaways from Q4 and Full-Year 2024 Earnings Report - HPBL
Cautious Outlook on Ginkgo Bioworks: Sell Rating Amid Financial and Strategic Concerns - TipRanks
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Call Transcript - Insider Monkey
Ginkgo Bioworks Holdings Inc (DNA) Q4 2024 Earnings Call Highlights: Strategic Restructuring ... By GuruFocus - Investing.com Canada
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates - MSN
Ginkgo Bioworks Reports Improved Q4 2024 Results - TipRanks
Ginkgo subleases part of HQ, looks to address $65M of excess space - The Business Journals
Ginkgo Bioworks Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financ - GuruFocus.com
Ginkgo Bioworks Holdings, Inc. SEC 10-K Report - TradingView
Ginkgo Bioworks Holdings, Inc. Q4 Loss Narrows - Nasdaq
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results - WV News
Ginkgo Bioworks (DNA) to Release Quarterly Earnings on Tuesday - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 18, 2022 – DNA - ACCESS Newswire
Ginkgo Bioworks (NYSE:DNA) Trading Down 6.3%What's Next? - MarketBeat
Volta Labs enhances Ginkgo Bioworks sequencing workflow By Investing.com - Investing.com Canada
Ginkgo Bioworks Integrates Callisto For Difficult-To-Automate Ngs Processes In Their High-Throughput Lab - Marketscreener.com
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab - Marketscreener.com
Ginkgo Bioworks integrates Callisto for difficult-to-automate NG - GuruFocus.com
Short Interest in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Rises By 5.4% - MarketBeat
Can This New Lab Automation System Transform Ginkgo's DNA Sequencing Capabilities? - StockTitan
Ginkgo Bioworks Partners With HaDEA on Up to $25.1 Million Project for Rapid Virus Diagnostics - Marketscreener.com
Ginkgo Bioworks Holdings Inc Partners With Hadea In Up To EUR 24 Million Consortium Project - Marketscreener.com
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care - Quantisnow
Can This €24M EU-Backed Diagnostic Technology Revolutionize Respiratory Virus Detection? - StockTitan
Ginkgo Bioworks Holdings, Inc. (DNA) Dips More Than Broader Market: What You Should Know - MSN
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation - BioSpace
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):